qfx

Let us not mourn these fallen angels. Let us sharpen our checklists and polish our wallets. When Wall Street suffers a collective nervous breakdown, the prudent investor hears not screams, but violins playing a waltz of opportunity.

Pfizer, of course, is a pharmaceutical giant, which means that the drugs it manufactures are as complicated as the finest French pastries. Years of research, trials, and regulatory approval are required before the company can launch a product-an arduous process that invites a certain protectionist benevolence from the government in the form of patent monopolies. How kind of them, really. Yet these monopolies, like all monopolies, are temporary. And when that magic period expires, the competition-like a swarm of eager locusts-descends with cheaper generics. The inevitable “patent cliff,” one might call it, is fast approaching, and naturally, investors have been abuzz with concern. How quaint.

Meme coins were the party crashers of crypto. Now? The music’s stopped. Investors tiptoe away, but Dogecoin clings to eighth place, a $32 billion punchline. Is it time to buy the dip? Or just time to admit the joke’s on us?

To confess error-a act as unnatural to boardrooms as milk to a vampire-is the first trembling step toward absolution. Filosa’s admission, though not born of his own sin, is a lantern in the fog. For Stellantis, a colossus teetering on rusted legs, the path forward demands more than mechanical recalibration. It requires the resurrection of the Jeep Cherokee-a ghost from the graveyard of discontinued models-to rise not merely as a vehicle, but as a sacrament of rebirth.